12
décembre 2023
10:47 E.S.T.
Preliminary Results of NatHaLi-01: A First-In-Human Phase I/IIa Study of UCART20x22, a Dual Allogeneic CAR-T Cell Product Targeting CD20 and CD22, in Relapsed or Refractory (R/R) Non-Hodgkin Lymphoma (NHL) - ASH 2023 - Présentation Poster
Télécharger le PDF